Enabling the Drug Discovery & Development Continuum – Hosted by Evotec

The first webinar of the series will outline how the blending of discovery and development teams and profiling activities, often considered only in development, within the lead optimisation (LO) phase facilitates a gradual and seamless transition into clinically enabling development rather than a discrete hand-over between traditionally separate organisations. This philosophy has been shown to deliver PDCs with enhanced “development quality” and hence increased likelihood of surviving downstream development pressures.

The presentation will also describe Evotec’s approaches to make better and more informed decisions to better manage development risks through a strong focus on human relevance as well as the prediction of outcomes, for example, with the use of machine learning and AI. In addition, for those outcomes that cannot be predicted, the benefits of revealing the unpredictable as early as possible in order to discharge or mitigate development risks will be discussed.